
PGY1 Internal Medicine @WeillCornell. Previously: PhD/Postdoc @CSHL Janowitz/Furukawa Lab, Doctor @NHSuk, MD @UniofOxford, BA @Cambridge_Uni.
New York City, NY
Joined March 2020
- Tweets146
- Following489
- Followers236
- Likes805
Pinned Tweet
Delighted to share that my PhD research studying the connection between anti-cancer immunity and autoimmunity, supervised by @JanowitzTobias and @Lab_FURUKAWA @CSHL has been published in @Nature today.
Nature research paper: Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity
go.nature.com/4t2PmcB
After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab nature.com/articles/s41591-0… @NatureMedicine
Sam Kleeman, MD PhD retweeted
Out now in Nature Medicine: a health-system-scale cachexia atlas (52K patients) that describes and predicts outcomes, with prospective risk models for lung, colorectal, and prostate cancer. Congrats to @EdReznik for a landmark paper for the field. nature.com/articles/s41591-0…
Sam Kleeman, MD PhD retweeted
Behavioral dysfunction but not wasting in cancer cachexia is driven by altered tryptophan metabolism
@CancerGrand @Ludwig_Cancer @RutgersCancer @Princeton
biorxiv.org/content/10.64898…
Sam Kleeman, MD PhD retweeted
Excited to share our new preprint: BRCA1/2 loss creates a PKM1-high metabolic state that can be therapeutically exploited.
Pushing pyruvate kinase activity further with the FDA-approved drug mitapivat selectively suppresses BRCA2-deficient tumors.
HRD may be more than a DNA repair defect—it may also be a targetable metabolic state.
Congrats @19_maira_90
biorxiv.org/content/10.64898…
Very happy to have contributed to this review with @VeredStearns @JCO_ASCO on personalized therapy for HER2-positive early breast cancer.
@WCMBreastCenter @WCM_MeyerCancer
Excellent summary of the NEW standard of care in Her2 positive disease. Time to abandon this one size fits all approach! #bcsm #breastcancer
Sam Kleeman, MD PhD retweeted
Excellent summary of the NEW standard of care in Her2 positive disease. Time to abandon this one size fits all approach! #bcsm #breastcancer
Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer
Great review👇
ascopubs.org/doi/10.1200/JCO…
Sam Kleeman, MD PhD retweeted
Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer
Great review👇
ascopubs.org/doi/10.1200/JCO…
Sam Kleeman, MD PhD retweeted
Arguably the most boring step in genomics is the first one: normalization. Settled science. Scale + log. Move on.
Except that here's been a huge blind spot in the field. And it matters for AIxBio. A 🧵about what I think may be one of the most important papers I've written. 1/
Sam Kleeman, MD PhD retweeted
Excited to present the first pre-print from our group, an investigation the human bone marrow microenvironments in patients with myelodysplastic syndromes (MDS) and normal age-matched subjects using Xenium genotype-informed spatial transcriptomics:
biorxiv.org/content/10.64898…
Sam Kleeman, MD PhD retweeted
Autoantibodies cause autoimmune disease, shape infection outcomes, and alter cancer immunotherapy. But what role might they play in neuropsychiatric disease? In our new preprint, Katlyn Nemani and @JillianRJaycox take on this question in schizophrenia. 🧵
biorxiv.org/content/10.64898…
Sam Kleeman, MD PhD retweeted
Register today for the next @WCMEnglanderIPM #PrecisionMedicine Research Conference, featuring Drs. Sam Oscar Kleeman (@KleemanSam) from @CSHL and Vered Stearns (@VeredStearns) from Weill Cornell Medicine! #BreastCancer #Biomarkers
Sam Kleeman, MD PhD retweeted
Immune surveillance can be a double-edged sword. ⚔️
In @Nature, Endeavor Awardee @JanowitzTobias shows that the same B cell response targeting NMDAR-expressing breast cancer tumors can mature into antibodies that trigger autoimmune disease.
nature.com/articles/s41586-0…
Sam Kleeman, MD PhD retweeted
Pleased to share our new collaborative work on the link between anti-cancer immunity and anti-NMDAR encephalitis. Clinical sample, mouse model, BCR seq, cryo-EM, electrophysiology, behavior, etc. @JanowitzTobias @KleemanSam and more. nature.com/articles/s41586-0…
Sam Kleeman, MD PhD retweeted
We are pleased to share our paper connecting anti-cancer immunity to autoimmune mediated neuropsychiatric disease. @KleemanSam @Lab_FURUKAWA @miriamferrer95 @jpreall @Mayo_AING @CSHL @NorthwellHealth @TBBCF @SimonsFdn @TheMarkFdn @NIH @BarbMarte nature.com/articles/s41586-0…
Thrilled to announce I have matched into the Internal Medicine-Research Track Program at @WeillCornell! #Match2026 @TheNRMP 🎉
Sam Kleeman, MD PhD retweeted
Early-career researchers thrive at CSHL! From the Janowitz lab, Sam Kleeman (@KleemanSam) has been selected for the 2026 Emerging-Generation Award, and Alice Wang has received a Predoctoral Fellowship award. Read more here! cshl.edu/janowitz-lab-member…
Sam Kleeman, MD PhD retweeted
Spatial transcriptomics is powerful—but fragile. Our new @NatureGenet paper shows that cell-segmentation errors are widespread and can obscure much of what we think we’re learning. nature.com/articles/s41588-0…
Honored to receive a 2026 Emerging-Generation (E-Gen) Award from @the_asci! I am incredibly grateful to my mentors Tobias Janowitz (@JanowitzTobias) and Hiro Furukawa (@Lab_FURUKAWA) for their support throughout my PhD @CSHL @CSHLsbs.
The ASCI is proud to announce our 2026 Early-Career Awardees!
The complete list of awardees:
E-Gen: buff.ly/p9Y25zR
YPSA: buff.ly/E81xVOZ
Congratulations to our award recipients and the institutions they represent!
Sam Kleeman, MD PhD retweeted
Our new paper in @TheLancetPsych
NMDAR-antibody is very different from most forms of psychosis.
- Rapid Onset
- Complex, Polysymptomatic features
- Often starts with mood
- Dynamic over a short timescale
- plus some more specific characteristics
url-shortener.me/2XKW























